SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Dou Haiqiang 1984)
 

Search: WFRF:(Dou Haiqiang 1984) > GLP-1 suppresses gl...

GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P/Q-type Ca2+ channels

Ramracheya, R. (author)
Chapman, C. (author)
Chibalina, M. (author)
show more...
Dou, Haiqiang, 1984 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
Miranda, Caroline (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
Gonzalez, A. (author)
Moritoh, Y. (author)
Shigeto, M. (author)
Zhang, Q. (author)
Braun, M. (author)
Clark, A. (author)
Johnson, P. R. (author)
Rorsman, Patrik, 1959 (author)
Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi,Institute of Neuroscience and Physiology
Briant, L. J. B. (author)
show less...
 (creator_code:org_t)
2018-09-05
2018
English.
In: Physiological Reports. - : Wiley. - 2051-817X. ; 6:17
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Glucagon is the body's main hyperglycemic hormone, and its secretion is dysregulated in type 2 diabetes mellitus (T2DM). The incretin hormone glucagon-like peptide-1 (GLP-1) is released from the gut and is used in T2DM therapy. Uniquely, it both stimulates insulin and inhibits glucagon secretion and thereby lowers plasma glucose levels. In this study, we have investigated the action of GLP-1 on glucagon release from human pancreatic islets. Immunocytochemistry revealed that only <0.5% of the alpha-cells possess detectable GLP-1R immunoreactivity. Despite this, GLP-1 inhibited glucagon secretion by 50-70%. This was due to a direct effect on alpha-cells, rather than paracrine signaling, because the inhibition was not reversed by the insulin receptor antagonist S961 or the somatostatin receptor-2 antagonist CYN154806. The inhibitory effect of GLP-1 on glucagon secretion was prevented by the PKA-inhibitor Rp-cAMPS and mimicked by the adenylate cyclase activator forskolin. Electrophysiological measurements revealed that GLP-1 decreased action potential height and depolarized interspike membrane potential. Mathematical modeling suggests both effects could result from inhibition of P/Q-type Ca2+ channels. In agreement with this, GLP-1 and omega-aga-toxin (a blocker of P/Q-type channels) inhibited glucagon secretion in islets depolarized by 70 mmol/L [K+](o), and these effects were not additive. Intracellular application of cAMP inhibited depolarization-evoked exocytosis in individual alpha-cells by a PKA-dependent (Rp-cAMPS-sensitive) mechanism. We propose that inhibition of glucagon secretion by GLP-1 involves activation of the few GLP-1 receptors present in the alpha-cell membrane. The resulting small elevation of cAMP leads to PKA-dependent inhibition of P/Q-type Ca2+ channels and suppression of glucagon exocytosis.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

cAMP
cyclic adenosine monophosphate
GLP-1
glucagon-like peptide 1
K-ATP
potassium ATP
protein-kinase-a
k-atp channels
beta-cells
delta-cells
human islets
fasting hyperglycemia
electrical-activity
potassium channels
glucose
regulation
insulin-secretion

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view